Therapy With 177 Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors

AJR Am J Roentgenol. 2019 Aug;213(2):309-317. doi: 10.2214/AJR.19.21123. Epub 2019 Apr 30.


OBJECTIVE. The purpose of this article is to enhance knowledge of the clinical implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of patients with neuroendocrine tumors. CONCLUSION. Most well differentiated and some moderately and poorly differentiated neuroendocrine tumors express large numbers of somatostatin receptors on their cell surfaces. PRRT targets these cells with 177Lu-DOTATATE, which is a medium-energy beta emitter. Since this agent received U.S. Food and Drug Administration approval in 2018, tremendous effort has been exerted at institutions throughout the United States toward proper implementation of this promising therapy. This review summarizes clinical implementation of PRRT and its impact on patient care.

Keywords: Lu-DOTATATE; lutetium 177; neuroendocrine tumors; peptide receptor radionuclide therapy.

Publication types

  • Review

MeSH terms

  • Humans
  • Neuroendocrine Tumors / radiotherapy*
  • Octreotide / analogs & derivatives*
  • Octreotide / therapeutic use
  • Organometallic Compounds / therapeutic use*
  • Somatostatin / metabolism


  • Organometallic Compounds
  • Somatostatin
  • lutetium Lu 177 dotatate
  • Octreotide